@entity440 related XXXX - A retrospective review.

@entity1 @entity1204 @entity0 @entity440 @entity242 @entity5 @entity3905 @entity3 @entity420
UNASSIGNED: 801 Background: @entity440 has been shown to significantly reduce the risk of @entity5 recurrence in @entity1 with @entity0 and has been used for chemoprevention in @entity1 with @entity3 and @entity1 at high risk of developing @entity0 . One established and accepted risk with this treatment is the increased risk of uterine @entity5 . Originally this was felt to be limited to @entity1204 , but recent evidence suggests an increased risk of @entity242 as well. METHODS: A 42-year retrospective review was performed at a rural tertiary care center. The charts of all @entity1 with a diagnosis of @entity242 were reviewed. 136 @entity1 with @entity242 were identifed. Any @entity1 with a primary diagnosis of @entity0 or use of @entity440 for adjuvant or preventive therapy were substratified. RESULTS: Of the 136 @entity1 with @entity242 , ten @entity1 had primary @entity0 . Six of these ten @entity1 had received a five-year course of @entity440 prior to the development of uterine sarsoma; four did not receive adjuvant hormonal therapy. Additionally, one of our @entity1 enrolled in the National Surgical Adjuvant Breast and Bowel Project (NSABP) @entity0 Prevention Trial developed a @entity3905 ( @entity3905 ) 27 months after completing a five-year course of @entity440 . CONCLUSIONS: We therefore report seven cases of @entity242 occurring subsequent to 60 months of @entity440 treatment. This is compared to the report of 12 cases identifed from the NSABP treatment and prevention trials secondary @entity5 data. We suggest that there may be a higher incidence of @entity242 in @entity440 -treated @entity1 than that based on the NSABP data. Given the increased risk of uterine @entity5 (both @entity420 and @entity242 ), as well as other potential complications of @entity440 use, consideration needs to be taken before beginning hormonal therapy, especially in a prevention setting. No significant financial relationships to disclose.
